Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

4.4K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.4K
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

346
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
346
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

2.0K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
2.0K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

334
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
334
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

375
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
375
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

370
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
370

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence and prognostic value of electrocardiographic changes in patients with myocardial injury after elective PCI.

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

Efficacy and Safety of Nanoencapsulated Sirolimus plus Pegadricase: Results from the Randomized, Placebo-Controlled Phase 3 Trials.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Design and rationale of the Radial Access Insertion Sheath Evaluation via the electronic medical record (RAISE-EMR) study.

American heart journal·2026
Same author

Contemporary Trends, Characteristics, and Outcomes of Patients Undergoing Percutaneous Coronary Intervention for Stent Thrombosis.

JACC. Cardiovascular interventions·2026
Same author

Drug-Coated Balloons for De Novo Non-aorto-ostial and Coronary Bifurcation Lesions: A Systematic Review and Meta-analysis.

Journal of the Society for Cardiovascular Angiography & Interventions·2026
Same author

Association of Race and Ethnicity With High-Potency P2Y12 Inhibitors Prescription Among Patients With Acute MI Undergoing PCI: An Analysis From the CathPCI Registry.

Circulation. Cardiovascular interventions·2026

Related Experiment Video

Updated: Apr 19, 2026

An Automated Method to Perform The In Vitro Micronucleus Assay using Multispectral Imaging Flow Cytometry
12:56

An Automated Method to Perform The In Vitro Micronucleus Assay using Multispectral Imaging Flow Cytometry

Published on: May 13, 2019

23.6K

Colchicine: old and new.

Anastasia Slobodnick1, Binita Shah2, Michael H Pillinger1

  • 1Department of Medicine, VA New York Harbor Health Care System, New York; Division of Rheumatology, Department of Medicine, NYU School of Medicine/NYU Langone Medical Center, New York.

The American Journal of Medicine
|January 3, 2015
PubMed
Summary
This summary is machine-generated.

Colchicine, an ancient drug, is now FDA-approved with updated dosing and new uses in rheumatic and cardiovascular diseases, owing to recent advances in its pharmacology and safety.

Keywords:
Cardiovascular diseaseColchicineGoutInflammation

More Related Videos

Detection of Inter-chromosomal Stable Aberrations by Multiple Fluorescence In Situ Hybridization mFISH and Spectral Karyotyping SKY in Irradiated Mice
10:14

Detection of Inter-chromosomal Stable Aberrations by Multiple Fluorescence In Situ Hybridization mFISH and Spectral Karyotyping SKY in Irradiated Mice

Published on: January 11, 2017

10.6K
Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
07:20

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

1.2K

Related Experiment Videos

Last Updated: Apr 19, 2026

An Automated Method to Perform The In Vitro Micronucleus Assay using Multispectral Imaging Flow Cytometry
12:56

An Automated Method to Perform The In Vitro Micronucleus Assay using Multispectral Imaging Flow Cytometry

Published on: May 13, 2019

23.6K
Detection of Inter-chromosomal Stable Aberrations by Multiple Fluorescence In Situ Hybridization mFISH and Spectral Karyotyping SKY in Irradiated Mice
10:14

Detection of Inter-chromosomal Stable Aberrations by Multiple Fluorescence In Situ Hybridization mFISH and Spectral Karyotyping SKY in Irradiated Mice

Published on: January 11, 2017

10.6K
Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
07:20

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

1.2K

Area of Science:

  • Pharmacology
  • Rheumatology
  • Cardiovascular Medicine

Background:

  • Colchicine has a long history of use and controversy.
  • Recent FDA approval in 2009 marked a new era for this drug.
  • Advances in understanding colchicine's pharmacology and safety have occurred over the last decade.

Purpose of the Study:

  • To review the pharmacologic properties of colchicine.
  • To summarize current knowledge on colchicine's mechanisms of action.
  • To update the use of colchicine in rheumatic and cardiovascular diseases.

Main Methods:

  • Literature review of colchicine's pharmacology.
  • Summary of research on mechanisms of action.
  • Discussion of current clinical applications.

Main Results:

  • Colchicine's pharmacologic profile has been elucidated.
  • Mechanisms of action are better understood.
  • Updated applications in rheumatic and cardiovascular conditions are presented.

Conclusions:

  • Colchicine's use has evolved significantly.
  • New insights support revised dosing and expanded therapeutic roles.
  • Colchicine remains a relevant therapeutic agent for diverse diseases.